Mark Sculpher
Professor

Profile

Biography

Mark Sculpher is Professor of Health Economics and is Director of the Programme on Economic Evaluation and Health Technology Assessment. He has been based at York University since 1997.

Between 1988 and 1997, he worked at the Health Economics Research Group at Brunel University; during 1998 he was a visitor in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Canada.

Mark has worked on economic evaluations of a range of technologies including heart disease and various cancers.  He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty.  He has over 170 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the economic evaluation of health care programmes (OUP, 2005 with Drummond, Torrance, O’Brien and Stoddart) and Decision modelling for health economic evaluation (OUP, 2006 with Briggs and Claxton).  

Mark was a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee between 2004 and 2008, the NICE Public Health Interventions Advisory Committee between 2006 and 2009 and currently sits on the NICE Diagnostics Advisory Committee.  He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and was a member of the Methods Working Party for the 2008 update of this guidance.  He was a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme between 2007 and 2010, and currently participates in the UK NIHR/Medical Research Council’s Methodology Panel.  Mark is a National Institute for Health Research Senior Investigator and is currently President-Elect of the International Society of Pharmacoeconomics and Outcomes Research.

Research

Overview

 

  • Decision analytic modelling, analysis of uncertainty and heterogeneity, economic evaluation and decision making

 

Research group(s)

Grants

  • National Institute for Health Research HTA Programme

Programme of Technology Assessment Reviews for the National Institute for Health and Clinical Excellence

Cost-effectiveness of endovascular aneurism repair

Long term cost-effectiveness of laparoscopic surgery versus medical management for gastro-oesophageal reflux disease

Evaluation of multi-functional magnetic resonance imaging in the diagnosis and characterisation of prostate cancer

  • National Institute for Health Research (NIHR)

Improving the quality of care of patients with angina and heart attack

Acupuncture for chronic pain and depression in primary care

Research Design Service – support in developing research by local clinicians and other researchers

  • NIHR/Medical Research Council Methodology Research Programme

Methods for estimation of the NICE cost-effectiveness threshold

  • British Heart Foundation

Cost-effectiveness of magnetic resonance imaging in coronary heart disease

Supervision

Mark Sculpher is part of the Thesis Advisory Group for:

  • Pedro Saramago, University of York, Department of Economics and Related Studies

Publications

Full publications list

2013

  • Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold. Centre for Health Economics, University of York, CHE Research Paper 81 (PDF , 3,944kb)‌ 2013.
  • Edlin R, McCabe C, Round J, Wright J, Claxton K, Sculpher M, Cookson R. Understanding Harris’ understanding of CEA: is cost effective resource allocation undone? Journal of Health Services Research and Policy. 2013;18(1)(1):34-9.
  • Faria R, McKenna C, Wade R, Yang H, Woolacott N, Sculpher M. The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. European Journal of Radiology 2013 doi.org/10.1016/j.ejrad.2013.
  • Grutters JPC, Sculpher MJ, Briggs AH, Severens JL, Candel MJ, Stahl SE, De Ruyssche D, Boer A, Ramaekers BLT, Joore MA. Acknowledging patient heterogeneity in economic evaluation.  A systematic literature review. Pharmacoeconomics. 2013;31(2)(2):111-23.
  • Sculpher MJ. Methods development for health technology assessment: is it time to set priorities? Medical Decision Making 2013;33(3):313-5. Download from sagepub
  • Walker S, Girardin F, McKenna C, Ball SG, Nixon J, Plein S, Greenwood JP, Sculpher M. Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. Heart 2013;doi:10.1136/heartjnl-2013-303624.

2012

  • Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. on behalf of the ISPOR-SMDMK Modelling Good Research Practices Task Force (2012).  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modelling Good Research Practices Task Force-6. Value in Health 2012;15(6):835-42.
  • Briggs AH, Weinstein MC, Fenwick E, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: A report of the ISPOR-SMDM Modelling Good Research Practices Task Force Working Group-6. Medical Decision Making 2012;32(5):722-32.
  • Ford JA, Waugh N, Sharma P, Sculpher MJ, Walker A. NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. BMJ Open 2012;2(1)doi:10.1136/bmjopen-2011-000671. Download from bmjopen
  • Garber AM, Sculpher M. Cost-effectiveness and payment policy. In: Pauly MV, McGuire TG, Barros PP, editors. Handbook in Health Economics. Oxford: Elsevier; 2012.
  • Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin S, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. Effect of treatment interruption and intensification of antiretroviral therapy on health related quality of life in patients with advanced HIV: a randomized, controlled trial. Medical Decision Making 2012;32(1):70-82. Download from sagepub
  • Manca A, Asseburg C, Bravo-Vergel Y, Seymour MT, Meade A, Stephens R, Parmar M, Sculpher MJ. The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). Value in Health 2012;15(1):22-31.
  • McKenna C, Wade R, Faria R, Yang H, Stirk L, Gummerson N, Sculpher M, Woolacott N. EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. Health Technology Assessment 2012;16(14):1-188. Download from HTA
  • Pitman RL, White LJ, Sculpher MJ. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine 2012;30:1208-24.
  • Revill P, Sculpher MJ. Cost effectiveness of interventions to tackle non-communicable diseases. British Medical Journal 2012;344:d7883.
  • Sculpher MJ, Claxton K. Real economics needs to reflect real decisions: (PDF , 177kb)‌‎ a response to Johnson. Pharmacoeconomics 2012;30:133-36.
  • Walker S, Griffin S, Claxton K, Palmer S, Sculpher M. Guest editorial, Appropriate perspectives for health care decisions. In: Curtis L, editor. Unit costs of health and social care 2012. Kent: PSSRU; 2012. p. 8-11. Download from pssru
  • Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Centre for Health Economics, University of York; CHE Research Paper 77 (PDF , 475kb)‌‎ 2012.
  • Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value in Health 2012;15(3):570-579. More details from Value in Health
  • Watt M, Mealing S, Eaton J, Piazza N, Moat N, Brasseur P, Palmer S, Busca R, Sculpher M. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 2012;98:370-76. Download from BMJ 

  • Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce I, Sculpher M, Woolacott N. Golimumab for the treatment of psoriatic arthritis: A NICE Single Technology Appraisal. Pharmacoeconomics 2012;30:257-70.

2011

  • Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin S, Nosyk B, Holodniy M, Brown ST, Sculpher M, Anis AH, Owens DK. Determinants of the cost of health services used by veterans with HIV. Medical Care 2011;49(9):848-56. Download from pubmed
  • Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, Sculpher M. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 2011;50:iv39-iv47.
  • Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer 2011;Nov 47(17):2517-30. Download from Sciencedirect
  • Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: its role, specification and prospects in a newly devolved NHS. Centre for Health Economics, University of York; CHE Research Paper 60 (PDF , 571kb)‌‎ 2011.
  • Griffin S, Claxton K, Palmer S, Sculpher M. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Economics 2011;20:212-24.  
  • Longworth L, Sculpher M, Bokje L, Tosh J. Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical Excellence. International Journal of Technology Assessment in Health Care 2011;27(2):180-7. Download from pubmed 
  • Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10):1-329. Download from HTA
  • Sullivan PW, Slejko JF, Sculpher MJ. Catalogue of EQ-5D Scores for the United Kingdom. Medical Decision Making 2011;31(6):800-804.
  • Walker S, Sculpher M, Drummond MF. The methods of cost-effectiveness analysis to inform decisions about the use of health care interventions and programmes. In: Smith PC, Glied S, editors. Oxford Handbook of Health Economics. Oxford: Oxford University Press;2011:p733-58.

2010

  • Barbieri M, Drummond M, Rutten F, Cook J, Glick H, Lis J, Reed SD, Sculpher M, Severens J. on behalf of the ISPOR Good Research Practices Economic Data Transferability Task Force. What do international pharmacoeconomic guidelines say about economic data transferability? Value in Health 2010;13:1028-37.
  • Bojke L, Claxton K, Bravo Vergel Y, Sculpher M, Palmer S, Abrams K. Eliciting distributions to populate decision analytic models. Value in Health 2010;13:557-64. Download from Wiley interscience 
  • Chambers D, Worthy G, Myers L, Weatherly H, Elliott R, Hawkins N, Sculpher M, Eastwood A. Glycopeptide versus non-glycopeptide antibiotics for prophylaxis of surgical site infections: a systematic review. Surg Infect 2010;11(5):455-62.
  • Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. Centre for Health Economics, University of York; CHE Research Paper 54 (PDF , 1,114kb)‌‎ , 2010.
  • Elliot RA, Weatherly HLA, Hawkins NS, Cranny G, Chambers D, Myers L, Eastwood A, Sculpher MJ. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? European Journal of Health Economics 2010;11(1):57-66. Download from springerlink
  • Griffin S, Rice N, Sculpher M. Economic evaluation of public health interventions. In: Killoran A, Kelly M, editors. Evidence-based public health: effectiveness and efficiency. Oxford: Oxford University Press; 2010.
  • Henriksson M, Palmer S, Chen R, Damant J, Fitzpatrick NK, Abrams K, Hingorani AD, Stenestrand U, Janzon M, Feder G, Keogh B, Shipley MJ, Kaski J-C, Timmis A, Sculpher M, Hemingway H. Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. British Medical Journal 2010;340:B5606.
  • Manca A, Sculpher M, Goeree R. The analysis of multinational cost effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments. Pharmacoeconomics 2010;28:1079-96.
  • McKenna C, Hawkins N, Claxton K, McDaid C, Suekarran S, Light K, Chester M, Cleland J, Woolacott N, Sculpher M. Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the UK. International Journal of Technology Assessment in Health Care 2010;26(2):175-82. Download from Pubmed.gov
  • Norman G, Soares M, Peura P, Rice S, Suh D, Wright K, Sculpher M, Eastwood A. Capecitabin for advanced gastric cancer. Health Technology Assessment 2010;14(s2). Download from  Pubmed
  • Paulden M, Rodgers M, Griffin S, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M. Alitretinoin for the treatment of severe chronic hand eczema. Health Technology Assessment 2010;14(s1):39-46. Download from NIHR
  • RESPECT Trial Team. Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. British Journal of General Practice. 2010;60:21-27.
  • Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Wollacott N, Sculpher M. Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal. Pharmacoeconomics 2010;28(5):351-62. Download from Pubmed
  • Sculpher M, Claxton K. Sins of omission and obfuscation: IQWiG’s guidelines on economic evaluation methods. Health Economics 2010;19(10):1132-36.
  • The United Kingdom EVAR Trial Investigators (Sculpher a member of the Writing Committee). Endovascular versus open repair for abdominal aortic aneurysm. New England Journal of Medicine 2010;362:1863-71. Download from NEJM
  •  Turnbull LW, Brown SR, Olivier C, Harvey I, Brown J, Drew P, Hanby A, Manca A, Napp V, Sculpher M, Walker LG, Walker S on behalf of the COMICE Trial Group. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision. Health Technology Assessment. 2010;14(1):pp1-182.
  • Wailoo AJ, Goodacre S, Sampson F, Hernandez M, Asseburg C, Palmer S, Sculpher M, Abrams K, de Belder MA, Gray H. Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty Project. Heart. 2010;96:668-72.
  • Walker S, Mason A, Claxton K, Cookson R, Fenwick E, Fleetcroft R, Sculpher M. Value for money and the quality and outcomes framework in primary care in the NHS. British Journal of General Practice 2010;60(574):213-20. Download from Ingentaconnect

2009

  • Barbieri M, Hawkins N, Sculpher MJ. Who does the numbers? The role of third-party technology assessments to inform health systems' decision-making about the funding of health technologies. Value in Health. 2009;12:193-201.
  • Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural uncertainty in decision-analytic models: a review and application of methods. Value in Health. 2009;12:739-49.
  • Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, Woolacott N. Rimonabant for the treatment of overwieght and obese people. Health Technology Assessment: 13:Suppl.3; 2009. Download from HTA
  • Chambers D, Epstein D, Walker S, Fayter D, Paton F, Wright K, Michaels J, Thomas S, Sculpher M, Woolacott N. Endovascular stents for abdominal aortic aneurysms: a systematic review and economic model. Health Technology Assessment 2009;13(48):pp1-214.
  • Cooke D, Hurel SJ, Casbard A, Steed L, Walker S, Meredith S, Nunn AJ, Manca A, Sculpher M et al. Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA1c in insulin-treated diabetes (MITRE Study). Diabetic Medicine. 2009;26(5):540-7. Download from Wiley Inter Science
  • Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, Reed S, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR Good Practices Task Force report. Value in Health. 2009;12:409-18
  • Epstein D, Bojke L, Sculpher M & the REFLUX trial group. The cost-effectiveness of laparoscopic fundoplication versus medical management for gastro oesophageal reflux disease. British Medical Journal 2009;338:b2576.
  • Greenwood JP, Maredia N, Radjenovic A, Brown JM, Nixon J, Farrin AJ, Dickinson C, Younger JF, Ridgeway JP, Sculpher M, Ball SG, Plain S. Clinical evaluation of magnetic resonance imaging in coronary heart disease: The CE-MARC study. Trials. 2009;10:p62 (doi:10.1186/745-6215-10-62).
  • Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advance squamous cell carcinmoa of the head and neck. Health Technology Assessment: 2009;13(s1):49-54. Download from HTA
  • Longworth L, Bojke L, Tosh J, Sculpher M. MRC-NICE scoping project: identifying the national institute for health and clinical excellence’s methodological research priorities and an initial set of priorities. Centre for Health Economics, University of York; CHE Research Paper 51 (PDF , 546kb)‌‎ 2009.
  • McDaid C, Duree KH, Griffin SC, Weatherly HLA, Stradling JR, Davies RJO, Sculpher MJ, Westwood ME. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome.Sleep Medicine Reviews 2009;13(6):427-36. Download from Sleep Medicine
  • McDaid C, Griffin S, Weatherly H, Duree KH, Burgt van der M, Hout van S, Akers J, Davies RJO, Sculpher M, Westwood M. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. Health Technology Assessment. 2009; 13(4) pp1-142.
  • McKenna C, McDaid C, Suekarran S, Hawkins N, Claxton K, Light K, Chester M, Cleland J, Woolacott N, Sculpher M. Enhanced external counterpulsation (EECP) for the treatment of stable angina and heart failure: A systematic review and economic analysis. Health Technology Assessment. 2009;13(24):1-112. Download from HTA
  • Newman SP, Cooke D, Casbard A, Walker S, Meredith S, Nunn A, Steed L, Manca A, Sculpher M, et al. A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). Health Technology Assessment. 2009;May;13(28):iii-iv, ix-xi, 1-194. Download from HTA
  • Sculpher MJ, Lozano-Ortaga G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, et al. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. American Heart Journal. 2009;157:845-52.
  • Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Sculpher M, et al. Methods for assessing the  cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy 209;93:85-92. Download from Health Policy
  • Weatherly HLA, Griffin S, McDaid C, Duree KH, Davies RJO, Stradling JR, Sculpher MJ et al. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. International Journal of Technology Assessment in Health Care. 2009;25(01):26-34.

2008

  • Al-Ruzzeh S, Epstein D, George S, Bustami M, Wray J, Ilsley C, Sculpher M, Amrani M. Economic evaluation of coronary artery bypass grafting surgery with and without cardiopulmonary bypass: cost-effectiveness and quality-adjusted life years in a randomized controlled trial. Artificial Organs. 2008;32(11):891-7. Download from Wiley Inter Science
  • Bojke L, Claxton K, Sculpher M, Palmer S, Philips Z. The cost-effectiveness and value for information associated with repeat screening for age related macular degeneration. Medical Decision Making. 2008;28:33-43. Download from Sage Journals Online
  • Bravo Vergel Y, Sculpher M. Quality-adjusted life years. Practical Neurology. 2008;8:175-82. Download from BMJ
  • Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walker S, Sculpher M. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251-4. Download from BMJ
  • Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, Sculpher M, Eastwood A.  A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery.  Health Technology Assessment 2008;12:1-168.
  • Culyer A, Sculpher M. Lessons from health technology assessment. In: Tompa E, Culyer A, Dolinschi R, eds. Economic evaluation of interventions for occupational health and safety. Oxford: Oxford University Press 2008.
  • Epstein D, Sculpher M, Clayton T, Henderson R, Pocock SJ, Buxton M, et al. Costs of an early intervention versus a conservative strategy in acute coronary syndrome. International Journal of Cardiology. 2008;127(2):240-6. Download from Science Direct
  • Epstein D, Sculpher M, Manca A, Michaels J, Thompson SG, Brown LC, et al. Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm. British Journal of Surgery. 2008;95:183-90. 
  • Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Medical Decision Making. 2008;28:21-32. Download from Sage Journals Online
  • Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial. Health Technology Assessment. 2008;12(31):1-204.
  • Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. Journal of Health Services Research and Policy. 2008;13:23-30. Download from RSM
  • Henriksson M, Epstein D, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart. 2008;94:717-23. Download from BMJ
  • Manca A, Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, Molet J, Thomson S, O'Callaghan J, Eisenberg E, Milbouw G, Buchser E, Fortini G, Richardson J, Taylor RJ, Goeree R, Sculpher MJ. Quality of life, resource consumption and costs of spinal cord simulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). European Journal of Pain. 2008;12:1047-58.
  • Mason A, Walker S, Claxton K, Cookson R, Fenwick E, Sculpher M. The GMS quality and outcomes framework: Are the quality and outcomes framework (QOF) indicators a cost-effective use of NHS resources? In: Quality and outcomes framework. Joint executive summary: Reports to the Department of Health from the University of East Anglia and the University of York. The GMS quality and outcomes framework (PDF , 238kb)‌‎
  • Ryan M, Griffin S, Chitah B, Walker SA, Mulenga V, Kalolo D, Hawkins N, Sculpher MJ, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. Aids. 2008;22:749-57.
  • Sculpher MJ. NICE's 2008 methods guide: sensible consolidation or opportunities missed? Pharmacoeconomics. 2008;26:721-4.
  • Sculpher MJ. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:799-806.

2007

  • Asseburg C, Bravo Vergel Y, Palmer S, Fenwick E, de Belder M, Abrams A, Sculpher M. Assessing the effectiveness of primary angioplasty compared to thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. Heart. 2007;93:1244-50. Download from BMJ
  • Bojke L, Hornby E, Sculpher M; on behalf of the REFLUX Trial Team. A comparison of the cost effectiveness of pharmacotherapy or surgery (laporoscopic fundoplication) in the treatment of GORD. Pharmacoeconomics. 2007;25(10):829-41. Download from Ingenta Connect
  • Bravo Vergal Y, Hawkins N, Claxton K, Asseburg C, Palmer S, Woolacoot N, Bruce IN, Sculpher MJ. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology. 2007;46:1729-35. Download from Oxford Journals
  • Bravo Vergel Y, Palmer S, Asseburg C, Fenwick E, De Belder M, Abrams A, Sculpher M. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart. 2007;93:1238-43. Download from BMJ
  • Briggs A, Mihaylova B, Sculpher M, et al. The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart. 2007;93:1081-6. 
  • Claxton K, Sculpher M, Culyer A. Mark versus Luke? Appropriate methods for the evaluation of public health interventions. Centre for Health Economics, University of York; CHE Research Paper 31 (PDF , 204kb)‌‎ 2007.
  • Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy. 2007;12:56-8.
  • Epstein D, Chalabi Z, Claxton K, Sculpher M. Efficiency, equity and budgetary policies: informing decisions using mathematical programming. Medical Decision Making. 2007;27:128-37.
  • Epstein D, Sculpher M, Manca A, Michaels J, Thompson S, et al. Endovascular repair versus open repair in patients with abdominal aortic aneurysm: a modelling study to estimate long term cost-effectiveness.  BJS In press.
  • Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost-effectiveness acceptability curves. Reprinted in: Culyer A, editor. Health economics: critical perspectives on the world economy. London: Routledge; 2007 (0415-35235-5).
  • Griffin SC, Barber JA, Manca A, Sculpher M, Thompson SG, Buxton MJ, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina. British Medical Journal. 2007;334(7594):624.
  • Griffin S, Claxton K, Hawkins N, Sculpher M. Decision models need to be fit for purpose for decision making: response to Caro et al. Value in Health. 2007;10(4):319. Download from Wiley Inter Science
  • Manca A, Lambert PC, Sculpher M, Rice N. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modelling. Medical Decision Making. 2007;27:471-90. Download from Sage Journals Online
  • Ossa DF, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia. Pharmacoeconomics. 2007;25:223-37.
  • Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytical cost-effectiveness models: a suggested framework and example of application. Reprinted in: Culyer A, editor. Health economics: critical perspectives on the world economy. London: Routledge; 2007 (0415-35235-5).
  • Suresh Punekar Y, Rodriguez-Roisin R, Sculpher M, Jones P, Spencer M, . Implications of chronic obstructive pulmonary disease (COPD) on patients health status: a western view Respiratory Medicine 2007;101:661-69. Download from Elsevier
  • Walker S, Palmer S, Sculpher M. The role of NICE technology appraisal in NHS rationing.British Medical Bulletin. 2007:1-14. Download from Oxford Journals

2006

  • Ades A, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probablistic sensitivity analysis. Health Economics. 2006;15:373-82.
  • Ades AE, Sculpher MJ, Sutton A, Abrams A, Cooper N, Welton N, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:2-29.
  • Bojke L, Claxton K, Palmer S, Sculpher M. Defining and characterising structural uncertainty in decision analytic models. Centre for Health Economics, University of York; CHE Research Paper 9 (PDF , 229kb)‌‎ , 2006.
  • Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press 2006.
  • Claxton K, Culyer AJ, Sculpher M, McCabe C, Briggs A, Akehurst R, Brazier J, Buxton M. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion (Editorial). Health Economics 2006;15:1-4.
  • Claxton K, Sculpher M. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24:1055-68.
  • Claxton K, Sculpher M, Fenwick E. Decision making with uncertainty. In: Jones AM, editor. Companion to health economics: Edward Elgar; 2006.
  • Drummond M, Sculpher M, Better analysis for better decisions: has pharmoeconomics come of age? Pharmacoeconomics 2006;24:107-108.
  • Drummond M, Sculpher M. Better analysis for better decisions: facing up to the challenges. Pharmacoeconomics. 2006;24:1039-42.
  • Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K, Sutton A. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimisation for patients undergoing major elective surgery. Medical Decision Making. 2006;26:480-96.
  • Griffin S, Claxton K, Hawkins N, Sculpher MJ (2006). Probabilistic analysis and computationally expensive models: necessary and required? Value in Health 2006:9;244-252.
  • Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality of assessment. Pharmacoeconomics. 2006;24:355-71.
  • Philips Z, Claxton KP, Palmer S, Bojke L, Sculpher MJ. Priority setting for research in health care: an application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome. International Journal of Technology Assessment in Health Care 2006;22:379-387.
  • Richardson G, Sculpher M, Kennedy A, Nelson E, Reeves D, Roberts C, et al. Is self-care a cost-effective use of resources? evidence from a randomised trial in inflammatory bowel disease. Journal of Health Services Research and Policy 2006;11(4):225-30. 
  • Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making. Health Economics, 2006;15:677-687.
  • Sculpher MJ, Drummond MF. Analysis sans frontiers: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics. 2006;24(11):1087-99.
  • Urdahl H, Manca A, Sculpher M. Assessing generalisability in model-based economic evaluation studies. A structured review in osteoporosis. Pharmacoeconomics. 2006;24(12):1181-97.
  • Whiting P, Westwood M, Bojke L, Palmer S, Richardson G, Cooper J, Watt I, Glanville J, Sculpher M, Kleijnen J. Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model. Health Technology Assessment 2006;10(36). 
  • Woolacott N, Bravo Vergel Y, Hawkins N, Khadjesari Z, Kaith A, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Chalmers R, Bruce I, Sculpher M, Riemsma R Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31):1-258.
  • Woolacoot N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R. Etanercept and Efalizumab for the treatment of psoriasis: a systematic review. Health Technology  Assessment 2006; 10(46):1-252.

2005

  • EVAR Trial Participants (2005). Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet, vol 365, pp2179-2186. (Mark Sculpher part of Trial Management Committee and Writing Committee).
  • EVAR Trial Participants (2005). Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet, vol 365, pp2187-2192. (Mark Sculpher part of Trial Management Committee and Writing Committee).
  • Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al. Should patients have a greater role in valuing health states? Applied Health Economics and Health Policy. 2005;4:201-8.
  • Drummond MF, Manca A, Sculpher MJ. Increasing the generalisability of economic evaluations: recommendations for the design, analysis and reporting of studies. International Journal of Technology Assessment in Health Care 2005;21(2):165-171.
  • Drummond MF, Sculpher MJ. Common methodological flaws in economic evaluations. Medical Care 2005;43(7 Suppl):115-14.
  • Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programme. Third edition: Oxford: Oxford University Press; 2005.
  • Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technology Assessment 2005;9(39):1-76.
  • Epstein D, Chalabi Z, Claxton K, Sculpher M. Mathematical programming for the optimal allocation of health care resources.  INCOMPLETE REFERENCE
  • Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Centre for Health Economics, York; CHE Research Paper 5 (PDF , 251kb)‌‎ , 2005.
  • Ginnelly L, Claxton K, Sculpher MJ, Golder S. Using value of information analysis to inform publicly funded research priorities. Applied Health Economics and Health Policy 2005;4:37-46.
  • Ginnelly L, Sculpher M, Bojke C, DiGuseppi C, Roberts I, Wade A. Determining the cost effectiveness of a smoke alarm give-away program using data from a randomised controlled trial. European Journal of Public Health 2005;15:448-453.
  • Hawkins N, Epstein D, Drummond M, Wilby J, Kainth A, Chadwick DM, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Medical Decision Making 2005;25:493-510.
  • Hawkins N, Sculpher M, Epstein D. Cost-effectiveness analysis of treaments for chronic disease: using R to incorporate time dependency of treatment response. Medical Decision Making 2005;25:511-519.
  • Hawkins N, Sculpher M, Rothman M. Modelling the cost-effectiveness of cardiac interventions: the case of sirolimus-eluting stents. British Journal of Cardiology. 2005;12:AIC83-AIC91.
  • Kim J, Henderson RA, Pocock SJ, Clayton T, Sculpher MJ, Fox KAA, Investigators. ftR-T. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: One-year results of the third randomized intervention trial of unstable angina (RITA-3). Journal of the American College of Cardiology 2005;45(2):221-228.
  • Longworth L, Buxton MJ, Sculpher MJ, Smith DH. Estimating utility data from clinical indicators for patients with stable angina. The European Journal of Health Economics 2005;6:347-353.
  • Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial based cost effectiveness analysis: the use of multilevel models. Health Economics 2005;14(5):471-485.
  • Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Economics 2005;14(5):487-496.
  • O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005;23:529-36.
  • Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service? International Journal of Cardiology 2005;100(2):229-240.
  • Robinson M, Palmer S, Sculpher MJ, Philips Z, Ginnelly L, Bowens A, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision analytic modelling. Health Technology Assessment 2005;9:1-172.
  • Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient eveidence Value in Health. 2005;8:433-46.
  • Sculpher M, Claxton K, Akehurst R. It's just evaluation for decision-making: recent developments in, and challenges for, cost-effectiveness research. In: Smith PC, Ginnelly L, Sculpher M, editors. Health policy and economics: opportunities and challenges. Maidenhead: Open University Press; 2005. p. 8-41.
  • Smith PC, Ginnelly L, Sculpher M. (eds) Health policy and economics. Opportunities and challenges. Maidenhead: Open University Press; 2004.
  • Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C. A rapid and systematic review of the clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults. Health Technology Assessment 2005;9(15):1-172.

Recent presentations

Teaching

Other teaching

Centre for Health Economics

 

External activities

Memberships

Editorial duties

Recent Presentations

Staff Photo for Mark Sculpher

Contact details

Mark Sculpher
Professor
Centre for Health Economics